{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:28:50Z","timestamp":1789777730894,"version":"4.0.1"},"reference-count":44,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"unspecified","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014461","name":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust\/Institute of Cancer Research","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["RCCCTF-Oct23\/100004"],"award-info":[{"award-number":["RCCCTF-Oct23\/100004"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Institute of Cancer Research Clinical Trials and Statistics Unit","award":["CTUQQR-Dec22\/100004"],"award-info":[{"award-number":["CTUQQR-Dec22\/100004"]}]},{"DOI":"10.13039\/501100020013","name":"NIHR Leicester Biomedical Research Centre","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100020013","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIHR\/CRUK Leicester Experimental Cancer Medicine Centre","award":["ECMCQQR-2022\/100006"],"award-info":[{"award-number":["ECMCQQR-2022\/100006"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjonc"],"accepted":{"date-parts":[[2026,8,3]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"\n Objectives<\/jats:title>\n Decentralised clinical trials (DCTs) are increasingly promoted in UK research policy and practice; however, their benefits and implementation challenges in oncology remain unclear. We examined DCT use in oncology through a review of studies evaluating decentralised oncology trial delivery, UK regulatory and policy frameworks and a survey of UK academic Clinical Trials Units (CTUs).<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Multimethod study including a structured literature review, policy review and cross-sectional survey of UK Clinical Research Collaboration (UKCRC)-registered CTUs.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n International literature, UK-based regulatory and policy documents and survey data from UKCRC-registered CTUs.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n None.<\/jats:p>\n <\/jats:sec>\n \n Main outcome measures<\/jats:title>\n Literature review: decentralised components evaluated and reported outcomes.<\/jats:p>\n Policy review: opportunities, barriers and gaps in UK regulatory and policy guidance relevant to DCTs.<\/jats:p>\n Survey: CTU awareness, uptake, perceived benefits and challenges related to decentralised trial delivery, comparing oncology and non-oncology settings.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 68 studies meeting broader eligibility criteria, only 8 formally evaluated decentralised elements within oncology trials and were included in the primary synthesis. Conducted across five countries, these studies primarily assessed feasibility, recruitment, usability and data completeness. Only one UK oncology study formally evaluated DCT methods, assessing use of remote electronic consent to support recruitment during the COVID-19 pandemic, highlighting limited published UK evaluation. Non-UK studies showed mixed findings, including improvements in trial processes or participant satisfaction in some contexts alongside operational challenges in others.<\/jats:p>\n The UK-based policy review identified strategic support for decentralisation but fragmented regulatory guidance and ambiguity around key decentralisation concepts. Temporary COVID-19-induced flexibilities demonstrated feasibility but have not been fully incorporated into permanent guidance.<\/jats:p>\n Survey responses were received from 27 CTUs (54% response rate). Awareness of decentralised approaches was high; however, use of these was lower in oncology than in non-oncology trials. Decentralisation was most commonly applied to patient follow-up. CTUs reported reduced participant burden and increased flexibility, but also challenges relating to governance, contracting, infrastructure, staffing and data management.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Decentralised approaches in UK oncology trials are gaining momentum but remain unevenly adopted, alongside a limited oncology-specific evidence base, regulatory ambiguity and operational challenges. Oncology presents distinct challenges that may limit decentralisation of trials compared with other disease areas, including complex interventions, intensive safety monitoring requirements and protocol-specific assessments. Evidence on patient\/public involvement and acceptability of decentralised approaches among people with cancer remains limited. Clearer guidance and more robust evaluation, incorporating patient perspectives, are needed to support wider implementation in the UK and may also be relevant internationally.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/bmjonc-2026-001145","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:15:14Z","timestamp":1787231714000},"page":"e001145","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Decentralised Oncology Trials in the UK: Evidence, Regulation and Academic Clinical Trials Units\u2019 Perspectives"],"prefix":"10.1136","volume":"5","clinical-trial-number":[{"clinical-trial-number":"nct04862143","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04380337","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03317990","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02620852","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04644315","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02376166","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2585-2807","authenticated-orcid":false,"given":"Oyeyemi","family":"Akala","sequence":"first","affiliation":[{"name":"Clinical Trials & Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK"},{"name":"Leicester Cancer Research Centre, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet S","family":"Walter","sequence":"additional","affiliation":[{"name":"Leicester Cancer Research Centre, University of Leicester, Leicester, UK"},{"name":"CRUK\/NIHR Leicester Experimental Cancer Medicine Centre, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Snowdon","sequence":"additional","affiliation":[{"name":"Clinical Trials & Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianina-Ioana","family":"Postavaru","sequence":"additional","affiliation":[{"name":"School of Psychology and Vision Sciences, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith M","family":"Bliss","sequence":"additional","affiliation":[{"name":"Clinical Trials & Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Gribble","sequence":"additional","affiliation":[{"name":"Clinical Trials & Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Botschka","sequence":"additional","affiliation":[{"name":"Clinical Trials & Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0973-660X","authenticated-orcid":false,"given":"Fay H","family":"Cafferty","sequence":"additional","affiliation":[{"name":"Clinical Trials & Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2026082006150595000_5.2.e001145.1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/bmjebm-2023-112253","article-title":"Digitally enabled decentralised research: opportunities to improve the efficiency of clinical trials and observational studies","volume":"28","author":"Aiyegbusi","year":"2023","journal-title":"BMJ EBM"},{"key":"2026082006150595000_5.2.e001145.2","unstructured":"O\u2019Shaughnessy J . Commercial clinical trials in the UK: the lord o\u2019shaughnessy review final report. London UK Government; 2023."},{"key":"2026082006150595000_5.2.e001145.3","unstructured":"Saving and improving lives: the future of uk clinical research delivery. London Department of Health and Social Care; 2021."},{"key":"2026082006150595000_5.2.e001145.4","unstructured":"10 year health plan for england: fit for the future. London Department of Health and Social Care; 2025."},{"key":"2026082006150595000_5.2.e001145.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103520"},{"key":"2026082006150595000_5.2.e001145.6","unstructured":"Food and Drug Administration . Conducting clinical trials with decentralized elements: guidance for industry, investigators, and other stakeholders. Silver Spring (MD): FDA, 2024."},{"key":"2026082006150595000_5.2.e001145.7","unstructured":"European Medicines Agency . Recommendation paper on decentralised elements in clinical trials. 2025. Available: https:\/\/health.ec.europa.eu\/system\/files\/2023-03\/mp_decentralised-elements_clinical-trials_rec_en.pdf [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.8","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1111\/bcp.15205","article-title":"A systematic review of methods used to conduct decentralised clinical trials","volume":"88","author":"Rogers","year":"2022","journal-title":"Brit J Clinical Pharma"},{"key":"2026082006150595000_5.2.e001145.9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0850"},{"key":"2026082006150595000_5.2.e001145.10","unstructured":"Jisc . Jisc online surveys. 2024. Available: https:\/\/onlinesurveys.jisc.ac.uk\/ [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.11","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1111\/cas.15792","article-title":"First experience of a fully decentralized clinical trial: The dawn of a new era in oncology","volume":"114","author":"Taniguchi","year":"2023","journal-title":"Cancer Sci"},{"key":"2026082006150595000_5.2.e001145.12","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae050","article-title":"Advancing clinical trial equity through integration of telehealth and decentralized treatment","volume":"8","author":"Brown","year":"2024","journal-title":"JNCI Cancer Spectr"},{"key":"2026082006150595000_5.2.e001145.13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/1538-7445.SABCS21-P5-19-01","article-title":"Abstract P5-19-01: The impact of streamlined processes and patient-directed messaging to improve enrollment in a remote, pragmatic clinical trial","volume":"82","author":"Choy","year":"2022","journal-title":"Cancer Res"},{"key":"2026082006150595000_5.2.e001145.14","doi-asserted-by":"crossref","first-page":"S503","DOI":"10.1016\/S0302-2838(22)00411-0","article-title":"E-Consent \u2013 an innovative solution to maintain recruitment momentum in clinical trials during the COVID-19 pandemic","volume":"81","author":"Almeida-Magana","year":"2022","journal-title":"Eur Urol"},{"key":"2026082006150595000_5.2.e001145.15","first-page":"1","article-title":"Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer","volume":"1","author":"Galsky","year":"2017","journal-title":"JCO Clin Cancer Inform"},{"key":"2026082006150595000_5.2.e001145.16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.tipsro.2022.10.005","article-title":"Performance and usability evaluation of a mobile health data capture application in clinical cancer trials follow-up","volume":"24","author":"Paulissen","year":"2022","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"key":"2026082006150595000_5.2.e001145.17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3155","article-title":"Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK -positive (ALK +) solid tumors in a histology-agnostic setting","volume":"39","author":"Kurzrock","year":"2021","journal-title":"JCO"},{"key":"2026082006150595000_5.2.e001145.18","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70328","article-title":"Decentralized Clinical Trials in the Era of Real\u2010World Evidence: A Critical Assessment of Recent Experiences","volume":"18","author":"Wang","year":"2025","journal-title":"Clinical Translational Sci"},{"key":"2026082006150595000_5.2.e001145.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-024-01214-5","article-title":"Lessons learned from an unsuccessful decentralized clinical trial in Oncology","volume":"7","author":"Valachis","year":"2024","journal-title":"NPJ Digit Med"},{"key":"2026082006150595000_5.2.e001145.20","unstructured":"Medicines for human use (clinical trials) regulations, SI 2004\/1031. 2004."},{"key":"2026082006150595000_5.2.e001145.21","unstructured":"Electronic identification and trust services for electronic transactions (amendment etc.) (EU exit) regulations, si 2019\/89. 2019."},{"key":"2026082006150595000_5.2.e001145.22","doi-asserted-by":"crossref","unstructured":"Medical devices regulations, SI 2002\/618. 2002.","DOI":"10.1016\/S1471-3918(02)80042-9"},{"key":"2026082006150595000_5.2.e001145.23","unstructured":"Data Protection Act, 2018."},{"key":"2026082006150595000_5.2.e001145.24","unstructured":"UK general data protection regulation, retained regulation (EU) 2016\/679. 2018."},{"key":"2026082006150595000_5.2.e001145.25","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use . ICH harmonised guideline integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). 2016. Available: https:\/\/www.ich.org\/page\/efficacy-guidelines [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.26","unstructured":"Health Research Authority . IRAS guidance: set up of research activity at NHS organisations (interventional research). 2023. Available: https:\/\/www.myresearchproject.org.uk\/help\/hlpinterventional.aspx [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.27","unstructured":"Medicines and Healthcare products Regulatory Agency . Oversight and monitoring in clinical trials. 2022. Available: https:\/\/www.gov.uk\/government\/publications\/oversight-and-monitoring-of-investigational-medical-product-trials\/oversight-and-monitoring-activities [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.28","unstructured":"Medicines and Healthcare products Regulatory Agency, Health Research Authority . Joint statement on seeking and documenting consent using electronic methods (eConsent). 2018. Available: https:\/\/www.hra.nhs.uk\/about-us\/news-updates\/hra-and-mhra-publish-joint-statement-seeking-and-documenting-consent-using-electronic-methods-econsent\/ [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.29","unstructured":"Medicines and Healthcare products Regulatory Agency . Risk-adapted approach to clinical trials and risk assessments. 2022. Available: https:\/\/www.gov.uk\/government\/publications\/risk-adapted-approach-to-clinical-trials-and-risk-assessments [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.30","unstructured":"Medicines and Healthcare products Regulatory Agency . Good manufacturing practice and good distribution practice. 2014. Available: https:\/\/www.gov.uk\/guidance\/good-manufacturing-practice-and-good-distribution-practice [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.31","unstructured":"Medicines and Healthcare products Regulatory Agency . Regulating medical devices in the UK. 2020. Available: https:\/\/www.gov.uk\/guidance\/regulating-medical-devices-in-the-uk [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.32","unstructured":"32. Medicines and Healthcare products Regulatory Agency . MHRA position statement and guidance: electronic health records. 2015. Available: https:\/\/assets.publishing.service.gov.uk\/media\/5a80948940f0b62305b8bfa7\/Electronic_Health_Records_MHRA_Position_Statement.pdf [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.33","unstructured":"Medicines and Healthcare products Regulatory Agency . Access to electronic health records by sponsor representatives in clinical trials. 2020. Available: https:\/\/www.gov.uk\/guidance\/on-site-access-to-electronic-health-records-by-sponsor-representatives-in-clinical-trials [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.34","unstructured":"Medicines and Healthcare products Regulatory Agency . Managing clinical trials during coronavirus (COVID-19). 2020. Available: https:\/\/www.gov.uk\/guidance\/managing-clinical-trials-during-coronavirus-covid-19 [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.35","unstructured":"Health Research Authority . Making changes to a research study to manage the impact of COVID-19. 2021. Available: https:\/\/www.hra.nhs.uk\/covid-19-research\/covid-19-guidance-sponsors-sites-and-researchers\/ [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.36","unstructured":"Department of Health and Social Care . The future of clinical research delivery: 2022 to 2025 implementation plan. 2022. Available: https:\/\/www.gov.uk\/government\/publications\/the-future-of-uk-clinical-research-delivery-2022-to-2025-implementation-plan\/the-future-of-clinical-research-delivery-2022-to-2025-implementation-plan [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.37","unstructured":"Health Research Authority . Decentralised trial methods position statement. 2023. Available: https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/policies-standards-legislation\/clinical-trials-investigational-medicinal-products-ctimps\/decentralised-trial-methods-position-statement\/ [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.38","unstructured":"Decentralized Trials & Research Alliance . Glossary. Available: https:\/\/www.dtra.org\/glossary#letter-H [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.39","unstructured":"Clinical Trials Transformation Initiative . CTTI recommendations: decentralized clinical trials. 2018. Available: https:\/\/ctti-clinicaltrials.org\/wp-content\/uploads\/2021\/06\/CTTI_DCT_Recs.pdf [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.40","unstructured":"Castaneda R . Direct to patient: rocky road to remote drug delivery in clinical trials. 2022. Available: https:\/\/www.clinicaltrialsarena.com\/features\/direct-to-patient-the-rocky-road-to-remote-drug-delivery-in-clinical-trials\/?cf-view [Accessed 12 Mar 2026]."},{"key":"2026082006150595000_5.2.e001145.41","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/bcp.15003","article-title":"Learning from remote decentralised clinical trial experiences: A qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders","volume":"88","author":"Coyle","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026082006150595000_5.2.e001145.42","doi-asserted-by":"crossref","DOI":"10.1017\/cts.2025.69","article-title":"Participant experiences in a decentralized clinical trial using digital health technologies: The ACTIV-6 study","volume":"9","author":"Reale","year":"2025","journal-title":"J Clin Transl Sci"},{"key":"2026082006150595000_5.2.e001145.43","unstructured":"Transforming the UK clinical research system: August 2025 update; London Department of Health and Social Care; 2025."},{"key":"2026082006150595000_5.2.e001145.44","unstructured":"Health Research Authority . Guidance on changes to the clinical trials regulations. Available: https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/policies-standards-legislation\/clinical-trials-investigational-medicinal-products-ctimps\/clinical-trial-regulations-reform\/guidance-on-changes-to-the-clinical-trials-regulations\/ [Accessed 12 Mar 2026]."}],"container-title":["BMJ Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjonc-2026-001145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:15:32Z","timestamp":1787231732000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjoncology.bmj.com\/lookup\/doi\/10.1136\/bmjonc-2026-001145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,8,20]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjonc-2026-001145"],"URL":"https:\/\/doi.org\/10.1136\/bmjonc-2026-001145","relation":{},"ISSN":["2752-7948"],"issn-type":[{"value":"2752-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}